Outcome-Based Contracting

CMS 2019 Final Rule and the Scope of the 340B Program

In its final rule for 2018, the Centers for Medicare and Medicaid Services (CMS) reduced Medicare Part B reimbursement for 340B-acquired drugs from Average Sales Price (ASP) plus 6% to…

Read Full Article

Refining Cost Sharing: Barriers to Outcome-Based Agreements in the U.S.

WHAT ARE OUTCOMES-BASED AGREEMENTS (OBA)? Currently, market forces, including volume, competition, and Research & Development expenditures, determine the prices for pharmaceutical therapies in the U.S. market. However, as prices for…

Read Full Article

EU’s Medical Device Regulation: What’s the effect on pricing?

In 2020, all medical device companies will have completed the implementation of the new medical device regulation. Reading European Union (EU) Regulation 2017/745 of the European Parliament and of the…

Read Full Article